红斑狼疮患者瘦素及可溶性瘦素受体检测的临床意义

目的探讨血清瘦素（Lp）和可溶性瘦素受体（sLR）与不同临床分型的红斑狼疮（LE）及系统性红斑狼疮（SLE）病情活动程度的关系。方法于2004年6月至2005年12月对中国医科大学附属第二医院和中国医科大学附属第一医院的39例LE患者，同年龄、性别、体重指数（BMI）均相匹配的31名健康人对照，采用放射免疫法和酶联免疫吸附实验（ELISA）检测血清Lp和sLR水平。结果（1）与正常对照相比较，LE患者血清Lp水平增高和sLR水平下降，差异有统计学意义（P〈0．01），活动期SLE患者血清Lp水平增高和sLR水平下降尤为显著；但非活动期SLE、亚急性皮肤型红斑狼疮（SCLE）和盘状红斑狼疮（DLE）患者血清Lp和sLR水平差异无统计学意义（P〉0．05）。（2）Lp与BMI呈正相关，与sLR呈负相关；SLE患者的病情活动程度与血清Lp水平呈正相关，与sLR水平呈负相关（P〈0．01）。结论Lp和sLR水平异常可能与LE的发病密切相关     

冠心病患者血清瘦素及可溶性瘦素受体检测分析

目的:研究血清瘦素(Lp)及可溶性瘦素受体(sLR)水平与冠心病的关系。方法:应用放射免疫分析法(RIA)及酶联免疫吸附分析法(ELISA)检测34例冠心病患者及其36例对照者血清Lp、sLR、空腹血糖(FBG)、TC、TG、HDL、LDL、胰岛素(INS)、稳态模型(HOMA)评估胰岛素抵抗(IR)(HOMA-IR)、体质指数(BMI)、腰围、臀围、腰臀比(WHR)等临床指标,分析Lp、sLR与血脂、IR及冠心病的关系。结果:冠心病组Lp、INS及HOMA-IR水平明显高于对照组,sLR水平明显低于对照组(P<0.01)。Lp与BMI、腰围、臀围、INS、HOMA-IR、TC、TG呈正相关,与sLR呈负相关;sLR与Lp、BMI、腰围、臀围呈负相关(P<0.05或P<0.01)。结论:Lp及sLR异常与肥胖、血脂异常、IR密切相关,共同参与冠心病的发生发展。     

冠心病患者血浆瘦素与可溶性瘦素受体水平的相关性

目的:探讨冠心病患者血浆瘦素（leptin,Lep）及可溶性瘦素受体(soluble leptin receptor,sLR)水平的变化,并分析Lep与冠心病各危险因素的关系。方法: 选取冠心病患者180例,正常对照组60例。所有患者行冠脉造影检查,冠脉狭窄程度采用Genisin评分,酶联免疫法测定Lep、sLR浓度,同时检测总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、体质量指数(BMI)、腰围、臀围等指标,分析Lep、sLR与冠心病的的关系。结果: 冠心病患者lep水平显著高于对照组［（12±6） vs.（9±5）μg/L,P<0.01］,sLR水平显著低于对照组［（124±62） vs.（164±70）μg/L,P<0.01］,在调整年龄、血糖和血压后,两组间的差别有显著性意义。多元Logistic回归分析显示冠心病患者μg/L。Lep水平的升高独立于年龄、血压、血脂等危险因素。结论: 冠心病患者Lep水平与冠脉病变的严重程度呈正相关,而sLRs水平与冠脉病变严重程度呈负相关。     

瘦素抵抗与男性非酒精性脂肪肝的关系

研究瘦素抵抗和男性非酒精性脂肪肝(nonalcoholic fatty liver,NAFL)的关系。我们用放射免疫法检测52例NAFL患者和45例正常对照者血清中的瘦素水平,分析血清瘦素与男性NAFL患者以及与HOMA-IR(以HOMA模型计算胰岛素抵抗指数)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)等指标的关系。NAFL患者血清中的瘦素水平(6.75±1.32μg/ml)显著高于正常对照组(3.21±0.95μg/ml),P<0.01,且肥胖的NAFL患者血清中的瘦素水平(7.95±0.85ng/ml)显著高于非肥胖NAFL患者的瘦素水平(6.11±1.21μg/ml),P<0.01。NAFL患者血清中的FINS、HOMA-IR和TG水平均高于正常对照组,且NAFL患者血清瘦素水平与HOMA-IR呈负相关(r=0.521,P<0.05),与BMI呈正相关(r=0.718,P<0.00),与TG呈正相关(r=0.425,P<0.01)。男性NAFL患者存在着明显的瘦素抵抗,提示瘦素抵抗在NAFL的发病机制中具有十分重要的作用。     

活动期系统性红斑狼疮患者脂代谢紊乱与重要脏器损害的关系探讨

目的 探讨活动期系统性红斑狼疮(SLE)患者血脂水平变化与脏器损害的关系.方法 收集71例活动期SLE患者和30名健康对照者临床资料,分析血脂变化.结果 活动期SLE患者平均血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、载脂蛋白B100(apoB)水平均高于健康对照组,高密度脂蛋白胆固醇(HDL)、apoA1水平显著低于健康对照组(P<0.05或P<0.01).有重要脏器损害患者的病程较长,血清TC、TG、LDL和apoB水平显著高于无脏器损害患者(P<0.05或P<0.01),尤其并发心血管病患者更明显(P<0.01).TC、TG、LDL、apoB水平与病程呈正相关(P<0.05或P<0.01),与C3水平呈负相关(P<0.05或P<0.01),TC和LDL与C4水平呈负相关(P<0.05).结论 活动期SLE患者存在严重脂代谢紊乱,且脂代谢紊乱与病程、疾病活动性和重要脏器损害密切相关.     

2型糖尿病患者血瘦素水平与高血压的相关性研究

选择122例2型糖尿病患者,分为合并高血压组和血压正常组,各组又分别分为肥胖和非肥胖亚组.测定其体重指数(BMI)、空腹血糖(FBG)和胰岛素、糖化血红蛋白(HbA1c)及血清瘦素水平,并作相关性分析.结果显示,2型糖尿病患者高血压组与非高血压组间血清瘦素水平无差异(P＞0.05);血清瘦素水平与BMI、空腹胰岛素呈正相关关系(P＜0.01),与血压无明显相关性(P＞0.05);但在合并高血压组,血清瘦素水平与HbA1c呈负相关关系(P＜0.05).提示2型糖尿病患者的血清瘦素水平与血压无明显相关性,但合并高血压患者长时间血糖控制不良可能会导致血清瘦素水平的下降.     

系统性红斑狼疮患者外周血淋巴细胞穿孔素表达及糖皮质激素对穿孔素的影响

目的 研究系统性红斑狼疮(SLE)患者外周血淋巴细胞穿孔素(PF)表达与分布,PF水平与疾病活动的相关性,探讨PF在SLE发病机制中的作用,观察糖皮质激素治疗对PF表达的影响.方法 SLE活动期患者16例,健康对照者12名.用流式细胞仪检测外周血淋巴细胞PF、CD3、CD4或CD8表达,用直线相关分析PF水平与SLE疾病活动性评分(SLEDAI)的相关性;比较糖皮质激素治疗前后PF水平变化.结果 与健康对照组比较,SLE活动期患者组外周血PF+淋巴细胞的百分率显著增高(P<0.01),PF的平均荧光强度(PFMFI)增高(P<0.01),PF+CD8+CD3+淋巴细胞的百分率明显增加(P<0.01),差异均有统计学意义.SLE活动期患者外周血PP淋巴细胞百分率与SLEDAI呈正相关(r=0.673).经过短期大剂量糖皮质激素治疗,SLE活动期患者外周血淋巴细胞PF+细胞百分率和PFMFI都显著下降(P<0.05),差异有统计学意义.结论 SLE活动期患者PF高表达,主要分布于CD8+CD3+细胞;PF水平与SLE活动程度呈正相关;短期糖皮质激素治疗能够减少患者体内PF表达.     

初发2型糖尿病患者血脂联素和瘦素与胰岛素抵抗的关系

目的 研究初发2型糖尿病患者血脂联素和瘦素水平的变化及其与胰岛素抵抗的关系.方法 选择46例初发2型糖尿病患者,及与其体脂含量相匹配的糖耐量正常者43名,计算体重指数(BMI)和腰臀围比(WHR),并空腹采血,测定血糖(FPG)、血脂、真胰岛素(FTI)、胰岛素原(FPI)、脂联素和瘦素浓度,分析血清脂联素和瘦素水平的变化及其与胰岛素抵抗的关系.用胰岛素抵抗指数(HOMA-IR)评估胰岛素抵抗程度.结果 2型糖尿病组与正常对照组比较,年龄、BMI无统计学意义(P>0.05),三酰甘油、FPG及FPI和HOMA-IR明显升高(P<0.05或P<0.01),舒张压、脂联素水平明显降低(P<0.05或P<0.01);相关分析显示,脂联素与FPG、FTI、HOMA-IR、BMI、WHR呈负相关(P<0.05或P<0.01);瘦素与BMI、FTI、HOMA-IR、FPG呈正相关(P<0.05或P<0.01),与WHR无关.人血清脂联素和瘦素间无相关性.结论 人血清脂联素和瘦素与胰岛素抵抗密切相关,体脂含量相同的初发2型糖尿病患者血脂联素水平低于正常人.     

非酒精性脂肪性肝病患者血清瘦素与胰岛素抵抗的关系

目的通过检测非酒精性脂肪性肝病(NAFLD)患者血清瘦素(Lp)的水平,探讨血清瘦素与胰岛素抵抗的关系。方法应用RIA检测30例NAFLD患者及30例对照者血清Lp水平,并检测空腹血糖、总胆固醇、甘油三酯、C-肽、胰岛素、体质指数等临床指标,分析Lp与胰岛素抵抗、血脂及非酒精性脂肪性肝病的关系。结果 NAFLD患者的Lp、BMI、胰岛素及胰岛素抵抗指数(HOMAIR)均显著高于对照组(P0.05)。男、女NAFLD患者Lp水平均高于男、女对照组(P0.05)。以HOMAIR为因变量,Lp、BMI、C-肽、总胆固醇及甘油三酯作为自变量,进行多元逐步回归分析,瘦素为影响IR的主要因素。结论 Lp可促进胰岛素抵抗,提示Lp与NAFLD有密切的关系。     

功能性消化不良患者血清Ghrelin及瘦素水平变化

目的 探讨功能性消化不良(FD)患者血清Ghrelin及瘦素水平变化及其临床意义.方法 60例FD患者,其中餐后不适综合征(PDS)30例,上腹痛综合征(EPS)30例,健康对照者30名,分别采用酶联免疫法和放射免疫法检测血清Ghrelin及瘦素水平.结果 FD组血清Ghrelin水平较对照组明显减低(P<0.01);FD组血清瘦素水平也较对照组明显减低(P<0.05);PDS组血清Ghrelin和瘦素水平较对照组明显减低(P<0.01),且较EPS组明显减低(P<0.01);而EPS组血清Ghrelin和瘦素水平与对照组比较,差异无统计学意义(P>0.05).结论 FD患者血清Ghrelin和瘦素水平减低主要是由PDS患者血清水平改变所致.PDS的病理机制可能主要与胃肠运动异常相关;血清Ghrelin和瘦素在FD发病过程中存在相互作用,对其的检测可能有助于FD分型和指导治疗.     

Serum leptin levels in women with systemic lupus erythematosus

The purpose of this study was to evaluate serum leptin levels in systemic lupus erythematosus (SLE). Forty-one women with SLE were compared with 23 healthy women of similar age and body mass index (BMI). Clinical characteristics and Mexican systemic lupus erythematosus disease activity index (Mex-SLEDAI) score were assessed. Serum leptin levels (ng/dl) were measured by enzyme-linked immunosorbent assay (ELISA). Comparisons of leptin levels were made with the Mann-Whitney U-test. In a multiple regression analysis, those factors that could influence the leptin levels were adjusted. Patients with SLE had higher leptin levels than the control group (SLE median 31 vs control median 15, P=0.023). After adjusting by other variables, the serum leptin levels remained higher in SLE than in controls (P=0.02). Patients with SLE had no association between leptin levels and Mex-SLEDAI score, age, duration of disease, or prednisone doses. Those with SLE had higher leptin levels than controls. Further longitudinal studies are required to evaluate the role of this hormone in the exacerbations of SLE.     

Serum leptin in systemic lupus erythematosus

Leptin, a peptide hormone, plays an essential role in the regulation of body weight, the endocrine function, reproduction, the immune response and inflammation. The immune system, in turn, modifies leptin’s production. Systemic lupus erythematosus (SLE) is an autoimmunological disease characterized by widespread inflammation with possible involvement of each body organ and system. In this study, we assessed serum leptin levels in SLE patients and the control group in search for correlations between leptin concentrations and other markers’ level, the activity of the disease, its duration, the age of the patients and their bone mineral density. Blood samples were collected from 30 SLE and 30 control group women. Each SLE patient was matched with one from the control for age (±1 year) and the body mass index (BMI; ±1). Serum leptin levels were determined using the DRG Leptin ELISA Kit. Serum leptin levels in SLE patients ranged from 1.8 to 66.3 ng/ml (median value 7.5), and in control group it was 8.8 ng/ml (0.7–39.2) (NS). In SLE, serum leptin levels (after the logarithmic transformation) correlated with BMI (r = 0.89, P < 0.0001), the age (r = 0.34, P < 0.01) and the patients’ disease duration (r = 0.59, P < 0.0005). Serum leptin levels in SLE patients with arthritis (P < 0.05) and central nervous system (CNS) involvement (P = 0.05) were significantly lower in comparison with serum leptin levels in SLE patients without arthritis and CNS involvement. No correlation was found between serum leptin levels and the T-score. In the control group, the logarithmic transformation of serum leptin levels positively correlated with BMI (r = 0.52, P < 0.05). No differences in serum leptin levels were shown between SLE patients and the control group. However, we found correlation between BMI and serum leptin levels in both groups. Furthermore, serum leptin levels in SLE patients with arthritis and CNS involvement were significantly lower in comparison with SLE patients without arthritis and CNS involvement, which suggests that active chronic inflammation may lower plasma leptin concentrations.     

Serum leptin in systemic lupus erythematosus patients: Its correlation with disease activity and some disease parameters

Aim of the work

To evaluate serum leptin levels in systemic lupus erythematosus (SLE) patients and correlate these levels with clinical and laboratory parameters as well as disease activity using systemic lupus disease activity index (SLEDAI).

Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis

BACKGROUND: Hypoandrogenicity is common in obesity and in chronic inflammatory diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Adrenal androgens such as androstenedione (ASD) and dehydroepiandrosterone (DHEA) sulphate are low, which partly depends on the influence of TNF in chronic inflammatory diseases. Leptin is stimulated by TNF and is associated with hypoandrogenicity in non-inflammatory conditions. OBJECTIVE: To study the interrelation between serum levels of leptin and adrenal steroids in SLE and RA. METHODS: In a retrospective study, serum levels of leptin, ASD, DHEA, and 17-hydroxyprogesterone (17OHP) were measured by ELISA, and serum levels of cortisol by radioimmunoassay in 30 patients with RA, 32 with SLE, and 54 healthy control subjects (HS). RESULTS: In SLE and RA but not HS, serum levels of ASD correlated negatively with serum levels of leptin (p<0.01) independently of prior prednisolone treatment in patients with SLE (p = 0.013) and tended to be independent of prednisolone in patients with RA (p = 0.067). In a partial correlation analysis, this interrelation remained significant after controlling for daily prednisolone dose in both patient groups. In both patient groups, serum leptin levels correlated negatively with the molar ratio of serum ASD/serum cortisol and serum ASD/serum 17OHP, and positively with the molar ratio of serum DHEA/serum ASD. CONCLUSIONS: The negative correlation of serum leptin and ASD or, particularly, ASD/17OHP, together with its known anti-androgenic effects indicate that leptin is also involved in hypoandrogenicity in patients with SLE and RA. Leptin may be an important link between chronic inflammation and the hypoandrogenic state.     

信号转导与转录激活因子2基因在外周血中的高表达与系统性红斑狼疮的病情活动相关

目的 探讨系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMC)中信号转导与转录激活因子2(STAT2)实时定量表达与SLE疾病特异性和病情活动度的相关性.方法 收集144例SLE患者、27例非SLE患者与58名健康对照者的临床资料,取外周血抽提总RNA并逆转录成cDNA,运用SYBR green dye Ⅰ实时定量聚合酶链反应(real-time MR)法检测患者组和对照组的STAT2 mRNA表达水平的差异,并与病情活动度进行分组比较,分析其意义.结果 SLE患者组的STAT2定量表达(5.2±1.7)高于非SLE患者组和健康对照组(4.3±1.1,4.5±1.2,P均<0.01);SLE活动组的STAT2表达(5.2±1.5)高于非活动组(4.8±2.9,P<0.01);SLE患者组的STAT2表达与SLE疾病活动指数(SLEDAI)-2000和尿蛋白值之间呈正相关(r=0.317,0.309,P均<0.01),与血清补体C3水平呈负相关(r=-0.449,P<0.01).结论 转录因子STAT2在外周血细胞中的异常表达与SLE的发病机制有关,STAT2 mRNA定量表达水平的升高与SLE患者病情活动相关.     

IKB激酶在系统性红斑狼疮患者中表达及与干扰素-α产生的关系

目的 研究系统性红斑狼疮(SEE)患者外周血白细胞中IKB激酶(IKK-α)、干扰素(IFN)-αmRNA的表达,并检测血浆中IFN-α的水平,以探讨SLE患者中IKK-α在IFN-α产生中的作用.方法 SYBR green dye I实时定量聚合酶链反应(PCR)方法检测外周血白细胞IKK-α和IFN-α的表达;酶联免疫吸附试验(ELISA)法检测血清IFN-α的水平.结果 ①SLE患者外周血IKK-α mRNA表达高于对照组(P<0.05);在活动组SLE患者中IKK-α mRNA的表达高于非活动组SLE患者(P<0.01).②SLE患者IFN-αmRNA的表达低于对照组(P<0.01),IFN-α mRNA的表达在非活动组SLE患者中低于活动组SLE患者(P<0.01).③SLE患者血清中IFN-α的水平高于对照组(P<0.01),其中,活动组SLE患者血浆IFN-α水平显著高于非活动组患者(P<0.05);SLE患者血浆中IFN-α浓度与抗双链DNA(dsDNA)抗体呈正相关(P=0.001),与补体C3水平呈负相关(P=0.005).④SLE患者IKK-α mRNA的表达与血浆中IFN-α的水平呈正相关(P=0.001).结论 SLE患者IKK-α mRNA的表达明显增高,且与血浆中IFN-α的水平呈正相关;而血浆中IFN-α的水平与SLE的发病及病情活动相关,提示IKK-α可能在SLE的发病中发挥重要的作用.     

系统性红斑狼疮患者循环annexin Ⅱ水平的变化及临床意义

目的 探讨系统性红斑狼疮(SLE)患者血自细胞annexinⅡ的表达水平及其在SLE中的临床意义.方法 采用流式细胞术检测SLE患者35例,慢性肾炎患者10例,糖尿病肾病(DN)患者10例,健康对照组20名血白细胞annexinⅡ的表达水平,并分析其与临床指标间的相关性.采用t检验、方差分析及直线相关性分析进行统计学分析.结果 SLE、DN组患者血白细胞annexin Ⅱ水平[(7.1±2.9)%,(8.0+3.7)%]均显著低于健康对照组[(10.6±1.6)%](P<0.01,P<0.05);有活动性[(SLE疾病活动指数(SLEDAI)评分≥9分]的SLE患者annexinⅡ水平[(5.6±2.4)%]显著低于非活动性(SLEDAI评分<9分)的SLE患者[(7.8±2.8)%](P<0.05);SLE患者annexinⅡ水平与尿蛋白/肌酐呈负相关(r=-0.382,P<0.05),与血白蛋白呈正相关(r=0.439,P<0.01),与SLEDAI呈负相关(r=-0.417,P<0.05),与D-二聚体呈负相关(r=-0.336,P<0.05).结论 SLE患者血白细胞annexin Ⅱ表达水平降低,参与了SLE患者高凝和继发性纤溶亢进状态的发生发展的病理生理过程,可作为一种早期反映SLE血栓前状态的良好指标,对判断SLE的活动性及疗效有一定的帮助.

Abstract：

Objective To compare the level of Annexin Ⅱ in patients with systemic lupus erythematosus(SLE),diabetic nephropathy(DN),chronic glomerulonephritis and normal controls,and explorle the significance of the annexin Ⅱ in SLE.Methods Thirty-five cases of patients with SLE,ten cases of patients with DN,ten cases of patients with chronic glomerulonephritis were enrolled in this study,twenty cases of healthy controls were also enrolled.Circulating annexin Ⅱ in white blood cells was detected bv flow cytometry.Student's t test,variance analysis and Lineat correlation analysis were used for statistial analysis.Resuits Compared with healthy controls,the level of annexin Ⅱ in white blood cells in SLE patients (7.1±2.9)%and DN patients(8.0±3.7)%were significantly lower than that of the healthy controls(P<0.01,p<0.05).In the SLE group,the level of annexin Ⅱ of patients who had more active disease(SLEDAI≥9)decreased more thall those with less active disease(SLEDAI<9),(P<0.05).A positive correlation was found between annexin Ⅱ and serum albumin level(r:0.439,P<0.01),but negative correlation was found between annexin and urine protein/urine creatinine(r=-0.382,P<0.05),SLEDAI(r=-0.417,P<0.05),D-dimer(r=-0.336.p＜0.05) levels.Conclusion The level of annexin Ⅱ is decreased in patients with SLE,so it can renectthe abnormality of coagulation and fibrinolytic systems,and it may be used as a good indicator for prothrombotic status in SLE patients.It can be helpful to evaluatethe activity of the disease and the therapeutic efficacy.     

系统性红斑狼疮患者外周血单个核细胞增殖诱导配体及其受体的表达

目的 探讨系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMC)中增殖诱导配体(APRIL)及其受体B细胞成熟抗原(BCMA)、跨膜激活剂及钙调亲环素配体相互作用分子(TACI)mRNA的表达和意义.方法 应用实时定量聚合酶链反应(real-time PCR)技术,检测66例SLE患者及25名正常人PBMC中APRIL及其受体mRNA的表达,采用2-AACT对目标基因的表达量进行评估.结果 SLE活动组和缓解组的APRIL mRNA、BCMA mRNA和TACI mRNA的表达水平均明显高于正常对照组(均P<0.01);且SLE活动组的APRIL mRNA和TACI mRNA的表达水平显著高于SLE缓解组(分别P<0.01,P<0.05),BCMA mRNA的表达在SLE活动组与缓解组之间比较差异无统计学意义;此外,APRILmRNA和TACI mRNA在SLE肾损组的表达显著高于非肾损组(均P<0.01).结论 SLE患者PBMC中APRIL及其受体的表达水平增高,可能在SLE发病机制中发挥重要作用.     

系统性红斑狼疮患者外周血单个核细胞端粒保护蛋白TPP1及POT1基因表达的研究

目的 研究端粒保护蛋白TPP1及POT1基因在系统性红斑狼疮(SEE)患者与健康人外周血单个核细胞(PBMCs)的表达及其与SEE肾损、疾病活动度的相关性.方法 应用实时荧光定量聚合酶链反应检测SEE患者活动组28例、缓解组20例及健康对照组30例PBMCs TPP1、POT1 mRNA表达水平,并且与SEE患者临床指标进行相关性分析.结果 SLE组与健康对照组相比,TPP1及POT1基因表达明显降低(P均<0.01),活动组与缓解组均显著低于健康对照组(P均<0.05);POT1基因在活动组的表达显著低于缓解组(P<0.05);TPP1及POT1基因在肾损组的表达低于无肾损组(P<0.01),在SLE肾损患者中,尿蛋白定量与TPP1及POT1基因的表达水平呈负相关(P<0.05),尿白细胞与POT1基因呈负相关(P<0.05);红细胞沉降率、C反应蛋白、抗核抗体与TPP1、POT1基因的表达及SLE疾病活动指数(SLEDAI)评分没有相关性;POT1 mRNA的表达与血清IsG、SLEDAI评分呈负相关(P<0.05,P<0.01),与补体C3呈正相关(P<0.01);TPP1 mRNA的表达与血清IgG、SLEDAI评分及C3没有相关性.结论 端粒保护蛋白TPP1和POT1基因在SLE的发病中发挥重要作用,其参与了SLE肾脏损害的病理过程,POT1可作为SEE疾病活动的有效的评判指标.